Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related articles

Clinical manifestations and diagnosis of menopause

INTRODUCTION

Natural menopause is defined as the permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of amenorrhea without any other obvious pathological or physiological cause. It occurs at a median age of 51.4 years in normal women, and is a reflection of complete, or near complete, ovarian follicular depletion, with resulting hypoestrogenemia and high FSH concentrations (figure 1). Menopause before age 40 years is considered to be abnormal and is referred to as primary ovarian insufficiency (premature ovarian failure). The menopausal transition, or perimenopause, occurs after the reproductive years, but before menopause, and is characterized by irregular menstrual cycles, endocrine changes, and symptoms such as hot flashes.

This topic will review the clinical features and diagnosis of the menopausal transition and menopause. The physiology and epidemiology of menopause, postmenopausal hormone therapy, and primary ovarian insufficiency are reviewed separately. (See "Ovarian development and failure (menopause) in normal women" and "Postmenopausal hormone therapy: Benefits and risks" and "Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)".)

CLINICAL MANIFESTATIONS

The menopausal transition, or perimenopause, begins on average four years before the final menstrual period, and includes a number of physiologic changes that may affect a woman’s quality of life. It is characterized by irregular menstrual cycles and marked hormonal fluctuations, often accompanied by hot flashes, sleep disturbances, mood symptoms, and vaginal dryness [1-6]. (See 'Symptoms' below.) In addition, changes in lipids and bone loss begin to occur, both of which have implications for long-term health.

Virtually all women experience the menstrual irregularity and hormonal fluctuations prior to clinical menopause, up to 80 percent develop hot flashes (the most common menopausal symptom), but only 20 to 30 percent seek medical attention for treatment. (See 'Hot flashes' below.)

Much of the available information about the endocrine and clinical manifestations of the menopausal transition comes from a number of longitudinal cohort studies of midlife women [7-19], the largest of which, the Study of Women’s Health Across the Nation (SWAN), has followed a multiethnic, community-based cohort of over 3000 women ages 42 to 52 years for 15 years [7,12-14,16,17,20-29]. Based upon data from the cohort studies, a staging system was developed that is now considered to be the gold standard for characterizing reproductive aging from the reproductive years through menopause. The STRAW staging system (Stages of Reproductive Aging Workshop) includes definitions for the late reproductive years, the menopausal transition, perimenopause, menopause, and postmenopause (figure 2) [3]. Although the STRAW system has been used primarily for women’s health research, it is helpful in the clinical setting for patients and clinicians for assessing fertility potential, contraceptive needs, and potential need for hormone therapy.

                                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Feb 4, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Taffe JR, Dennerstein L. Menstrual patterns leading to the final menstrual period. Menopause 2002; 9:32.
  2. Miro F, Parker SW, Aspinall LJ, et al. Origins and consequences of the elongation of the human menstrual cycle during the menopausal transition: the FREEDOM Study. J Clin Endocrinol Metab 2004; 89:4910.
  3. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97:1159.
  4. Freeman EW, Sammel MD, Gracia CR, et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril 2005; 83:383.
  5. Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008; 15:603.
  6. Burger HG. Unpredictable endocrinology of the menopause transition: clinical, diagnostic and management implications. Menopause Int 2011; 17:153.
  7. Bromberger JT, Schott LL, Kravitz HM, et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry 2010; 67:598.
  8. Freeman EW, Grisso JA, Berlin J, et al. Symptom reports from a cohort of African American and white women in the late reproductive years. Menopause 2001; 8:33.
  9. Hollander LE, Freeman EW, Sammel MD, et al. Sleep quality, estradiol levels, and behavioral factors in late reproductive age women. Obstet Gynecol 2001; 98:391.
  10. Lee CG, Carr MC, Murdoch SJ, et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 2009; 94:1104.
  11. Maki PM, Freeman EW, Greendale GA, et al. Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition. Menopause 2010; 17:815.
  12. Santoro N, Brockwell S, Johnston J, et al. Helping midlife women predict the onset of the final menses: SWAN, the Study of Women's Health Across the Nation. Menopause 2007; 14:415.
  13. Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 2009; 54:2366.
  14. Neer RM, SWAN Investigators. Bone loss across the menopausal transition. Ann N Y Acad Sci 2010; 1192:66.
  15. Woods NF, Mitchell ES. Sleep symptoms during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. Sleep 2010; 33:539.
  16. Randolph JF Jr, Zheng H, Sowers MR, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011; 96:746.
  17. Randolph JF Jr, Sowers M, Gold EB, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003; 88:1516.
  18. Manson JM, Sammel MD, Freeman EW, Grisso JA. Racial differences in sex hormone levels in women approaching the transition to menopause. Fertil Steril 2001; 75:297.
  19. Su HI, Sammel MD, Freeman EW, et al. Body size affects measures of ovarian reserve in late reproductive age women. Menopause 2008; 15:857.
  20. Van Voorhis BJ, Santoro N, Harlow S, et al. The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol 2008; 112:101.
  21. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006; 96:1226.
  22. Randolph JF Jr, Sowers M, Bondarenko I, et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005; 90:6106.
  23. Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am 2011; 38:489.
  24. Bromberger JT, Assmann SF, Avis NE, et al. Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. Am J Epidemiol 2003; 158:347.
  25. Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstet Gynecol Clin North Am 2011; 38:519.
  26. Derby CA, Crawford SL, Pasternak RC, et al. Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation. Am J Epidemiol 2009; 169:1352.
  27. Woodard GA, Brooks MM, Barinas-Mitchell E, et al. Lipids, menopause, and early atherosclerosis in Study of Women's Health Across the Nation Heart women. Menopause 2011; 18:376.
  28. Sternfeld B, Wang H, Quesenberry CP Jr, et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. Am J Epidemiol 2004; 160:912.
  29. Randolph JF Jr, Crawford S, Dennerstein L, et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab 2006; 91:3034.
  30. Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999; 84:105.
  31. Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 1975; 55:699.
  32. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992; 14:103.
  33. Hee J, MacNaughton J, Bangah M, Burger HG. Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone. Maturitas 1993; 18:9.
  34. Hale GE, Manconi F, Luscombe G, Fraser IS. Quantitative measurements of menstrual blood loss in ovulatory and anovulatory cycles in middle- and late-reproductive age and the menopausal transition. Obstet Gynecol 2010; 115:249.
  35. van Disseldorp J, Faddy MJ, Themmen AP, et al. Relationship of serum antimüllerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008; 93:2129.
  36. Hall JE. Neuroendocrine physiology of the early and late menopause. Endocrinol Metab Clin North Am 2004; 33:637.
  37. Greendale GA, Ishii S, Huang MH, Karlamangla AS. Predicting the timeline to the final menstrual period: the study of women's health across the nation. J Clin Endocrinol Metab 2013; 98:1483.
  38. Broer SL, Eijkemans MJ, Scheffer GJ, et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab 2011; 96:2532.
  39. La Marca A, Sighinolfi G, Papaleo E, et al. Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. PLoS One 2013; 8:e57005.
  40. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005; 118 Suppl 12B:14.
  41. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005; 142:1003.
  42. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000; 96:351.
  43. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001; 76:874.
  44. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990; 592:52.
  45. McKinlay SM. The normal menopause transition: an overview. Maturitas 1996; 23:137.
  46. Kravitz HM, Ganz PA, Bromberger J, et al. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003; 10:19.
  47. Freedman RR, Roehrs TA. Sleep disturbance in menopause. Menopause 2007; 14:826.
  48. Juang KD, Wang SJ, Lu SR, et al. Hot flashes are associated with psychological symptoms of anxiety and depression in peri- and post- but not premenopausal women. Maturitas 2005; 52:119.
  49. Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002; 9:392.
  50. Bromberger JT, Meyer PM, Kravitz HM, et al. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health 2001; 91:1435.
  51. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 1994; 4:214.
  52. Schmidt PJ, Haq N, Rubinow DR. A longitudinal evaluation of the relationship between reproductive status and mood in perimenopausal women. Am J Psychiatry 2004; 161:2238.
  53. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry 2006; 63:385.
  54. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006; 63:375.
  55. Freeman EW, Sammel MD, Liu L, et al. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004; 61:62.
  56. Cohen LS, Soares CN, Joffe H. Diagnosis and management of mood disorders during the menopausal transition. Am J Med 2005; 118 Suppl 12B:93.
  57. Sarrel PM. Ovarian hormones and vaginal blood flow: using laser Doppler velocimetry to measure effects in a clinical trial of post-menopausal women. Int J Impot Res 1998; 10 Suppl 2:S91.
  58. Cutler WB, Garcia CR, McCoy N. Perimenopausal sexuality. Arch Sex Behav 1987; 16:225.
  59. Szoeke CE, Cicuttini F, Guthrie J, Dennerstein L. Self-reported arthritis and the menopause. Climacteric 2005; 8:49.
  60. Matthews KA, Wing RR, Kuller LH, et al. Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch Intern Med 1994; 154:2349.
  61. Blümel JE, Chedraui P, Baron G, et al. Menopause could be involved in the pathogenesis of muscle and joint aches in mid-aged women. Maturitas 2013; 75:94.
  62. Szoeke CE, Cicuttini FM, Guthrie JR, Dennerstein L. The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study. Climacteric 2008; 11:55.
  63. Dugan SA, Powell LH, Kravitz HM, et al. Musculoskeletal pain and menopausal status. Clin J Pain 2006; 22:325.
  64. Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005; 105:1063.
  65. Chlebowski RT, Cirillo DJ, Eaton CB, et al. Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. Menopause 2013; 20:600.
  66. MacGregor EA. Menstruation, sex hormones, and migraine. Neurol Clin 1997; 15:125.
  67. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000; 15:24.
  68. Elting MW, Kwee J, Korsen TJ, et al. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 2003; 79:1154.
  69. Black A, Francoeur D, Rowe T, et al. SOGC clinical practice guidelines: Canadian contraception consensus. J Obstet Gynaecol Can 2004; 26:219.
  70. Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flashes. Maturitas 1997; 27:203.